Robert Glenning - Eagle Pharmaceuticals Director
| EGRX Stock | USD 4.55 0.06 1.30% |
Director
Mr. Robert L. Glenning is Independent Director of Eagle Pharmaceuticals, Inc. since July 2016. Mr. Glenning has over 30 years of experience in the healthcare industry and since July 2016 has served as the president of the financial services and information service divisions and chief financial officer at Hackensack Meridian Health, a notforprofit healthcare organization that is the most comprehensive health delivery network in the state of New Jersey, with anticipated revenues of over 4 billion annually. From 2007 to June 2016, he served as executive vice president and chief financial officer of Hackensack University Health Network. From 2002 to 2007, Mr. Glenning served as an executive vice president and chief financial officer of Kaleida Health Inc., the largest healthcare system in western New York. Prior to Kaleida Health, he served as vice president and chief financial officer of acute care at Northeast Health and Albany Memorial Hospital since 2016.
| Age | 57 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677 |
| Phone | 201 326 5300 |
| Web | https://www.eagleus.com |
Eagle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eagle Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.17 in 2024, whereas Return On Equity is likely to drop 0.14 in 2024. At this time, Eagle Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 262.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 8.2 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Patricia Allen | Deciphera Pharmaceuticals LLC | 56 | |
| Richard Koo | Amphastar P | 77 | |
| Dennis Walsh | Deciphera Pharmaceuticals LLC | 50 | |
| Sam Gejdenson | Phibro Animal Health | 70 | |
| Jack Tyrrell | Regencell Bioscience Holdings | 69 | |
| Thomas Haughey | ANI Pharmaceuticals | 54 | |
| Mary Malanoski | Phibro Animal Health | 61 | |
| John Byom | Prestige Brand Holdings | 66 | |
| Gwen Melincoff | Collegium Pharmaceutical | 65 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| George Ireland | Regencell Bioscience Holdings | 56 | |
| John Freund | Collegium Pharmaceutical | 64 | |
| YiChung Chao | Regencell Bioscience Holdings | 60 | |
| David Gill | Evolus Inc | 63 | |
| Charles Hinkaty | Prestige Brand Holdings | 64 | |
| Fred Holubow | ANI Pharmaceuticals | 77 | |
| Kristine Romine | Evolus Inc | 53 | |
| Karah Parschauer | Evolus Inc | 40 | |
| Jeffrey Pontius | Regencell Bioscience Holdings | 58 | |
| Charles Brymer | Regencell Bioscience Holdings | 56 | |
| David Nash | ANI Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 |
Eagle Pharmaceuticals Leadership Team
Elected by the shareholders, the Eagle Pharmaceuticals' board of directors comprises two types of representatives: Eagle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eagle. The board's role is to monitor Eagle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eagle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eagle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Reiner Nowak, Exec | ||
| Sander Flaum, Independent Director | ||
| Steven Krill, Chief Scientific Officer | ||
| Scott Tarriff, CEO and President Director and Member of Executive Committee | ||
| David Pernock, Director | ||
| Adrian Hepner, Executive Vice President - Clinical Research, Medical & Regulatory Affairs | ||
| Edward Kay, Director | ||
| Douglas Braunstein, Director | ||
| John Kimmet, Ex Care | ||
| Valentin MD, Senior Development | ||
| Pete Meyers, CFO, Principal Financial Officer, Principal Accounting Officer | ||
| Michael Graves, Independent Director | ||
| Debra Hussain, Senior Commercial | ||
| Lisa Wilson, IR Contact Officer | ||
| David Riggs, CFO | ||
| Ryan Debski, General VP | ||
| Robert Glenning, Director | ||
| Brian Cahill, Chief Officer | ||
| Reed McClung, Executive Development | ||
| Paul Bruinenberg, Chief Medical Officer, Head - Research & Development | ||
| Gaozhong Zhu, Senior Development | ||
| Peter Grebow, Executive VP of RandD | ||
| Sherry Korczynski, Sr. VP of Marketing | ||
| Jay Moorin, Independent Chairman of the Board | ||
| Richard Edlin, Independent Director | ||
| Alain Schreiber, Independent Director | ||
| Daniel OConnor, Chief VP | ||
| Steven Ratoff, Independent Director |
Eagle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eagle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 116.97 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 87.54 % | ||||
| Number Of Shares Shorted | 1.21 M | ||||
| Price To Earning | 40.52 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eagle Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eagle Pharmaceuticals' short interest history, or implied volatility extrapolated from Eagle Pharmaceuticals options trading.
Pair Trading with Eagle Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eagle Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eagle Stock
| 0.45 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Eagle Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eagle Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eagle Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eagle Pharmaceuticals to buy it.
The correlation of Eagle Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eagle Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eagle Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eagle Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Eagle Stock analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share 0.85 | Revenue Per Share 19.684 | Quarterly Revenue Growth (0.13) | Return On Assets 0.0663 |
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.